ribavirin has been researched along with Fatty Liver in 68 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 33 (48.53) | 29.6817 |
2010's | 35 (51.47) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Avram, L; Craciun, R; Crisan, D; Crisan, N; Epure, F; Grigorescu, M; Grigorescu, MD; Leach, N; Lupsor, M; Radu, C; Suciu, A | 1 |
Crisan, D; Grigorescu, M; Grigorescu, MD; Radu, C; Suciu, A | 1 |
Kanda, T; Moriyama, M | 1 |
Arai, M; Chiba, T; Imazeki, F; Kanda, T; Mikata, R; Nakamoto, S; Nakamura, M; Shirasawa, H; Tawada, A; Wu, S; Yasui, S; Yokosuka, O | 1 |
Chang, KC; Chen, CH; Hu, TH; Hung, CH; Kuo, FY; Lin, JT; Lin, MT; Lu, SN; Tsai, MC; Tseng, PL; Wang, JH; Wu, CK; Yen, YH | 1 |
Akuta, N; Arase, Y; Fujiyama, S; Hosaka, T; Ikeda, K; Kawamura, Y; Kobayashi, M; Kominami, Y; Kumada, H; Ohya, K; Saitoh, S; Sezaki, H; Suzuki, F; Suzuki, Y | 1 |
Izumi, T; Kawagishi, N; Kimura, M; Kudo, Y; Maehara, O; Miyoshi, H; Morikawa, K; Nakai, M; Nakamura, A; Natsuizaka, M; Nishida, M; Ogawa, K; Ohara, M; Sakamoto, N; Sho, T; Suda, G; Suzuki, K; Umemura, M | 1 |
Berger, F; Boesecke, C; Buendgens, L; Christensen, S; Hüppe, D; Ingiliz, P; Lutz, T; Mauss, S; Schewe, K; Simon, KG; Tacke, F | 1 |
Cooper, CL; Crawley, A; Doyle, MA; Galanakis, C; Mulvihill, E | 1 |
Hisanaga, Y; Kanamori, A; Kiriyama, S; Kitabatake, S; Kumada, T; Murakami, Y; Tada, T; Tanikawa, M; Toyoda, H | 1 |
Beinhardt, S; Ferenci, P; Hofer, H; Rutter, K; Scherzer, TM; Stättermayer, AF; Steindl-Munda, P; Strasser, M; Trauner, M; Wrba, F | 1 |
Aziz, S; Mirza, T; Sohail, S | 1 |
Callanan, M; Fugier, E; Hoang, XS; Jouvin-Marche, E; Leroy, V; Macek Jílková, Z; Marche, H; Marche, PN; Marlu, A; Sturm, N; Thelu, MA; Van Campenhout, N; Zarski, JP | 1 |
Barrero Alor, F; Casado Monge, PG; Jiménez Macías, FM; Pujol de la Llave, E; Ramos Lora, M; Ruíz-Frutos, C | 1 |
Chen, DS; Chen, PJ; Chung, CS; Kao, JH; Liang, CC; Lin, CK; Liu, CH; Liu, CJ; Su, TH; Yang, HC | 1 |
Efinger, M; Herrmann, E; Lange, CM; von Wagner, M; Welsch, C; Welzel, TM; Zeuzem, S | 1 |
Anand, B; Barange, K; Diago, M; Govindarajan, S; Hooper, G; Lin, A; Morgan, T; Rodriguez-Torres, M; Shiffman, M; Suter, F | 1 |
Fehér, J; Hagymási, K | 1 |
Barreiro, P; Soriano, V; Tuma, P; Vispo, E | 1 |
Bonkovsky, HL; Chung, RT; Di Bisceglie, AM; Everhart, JE; Everson, GT; Ghany, MG; Greenson, JK; Hoefs, JC; Kim, HY; Lee, WM; Lindsay, KL; Lok, AS; Morishima, C; Sterling, RK | 1 |
Fujita, N; Hara, N; Iwasa, M; Kaito, M; Kobayashi, Y; Kojima, Y; Miyachi, H; Takei, Y; Takeo, M; Tanaka, H | 1 |
Dinya, E; Schaff, Z; Tulassay, Z; Werling, K | 1 |
Ansaldi, F; Borro, P; Gentile, R; Icardi, G; Ravetti, G; Sumberaz, A; Testino, G | 1 |
Banasch, M; Ellrichmann, M; Meier, JJ; Schmidt, WE; Schrader, H; Vollmer, K | 1 |
Cross, TJ; Harrison, PM; Hughes, S; Nolan, J; Quaglia, A | 1 |
Abdurakhmanov, D; Bakulin, I; Cheinquer, H; Geyvandova, N; Harrison, SA; McKenna, M; Morozov, V; Rabbia, M; Reddy, KR; Rodriguez-Torres, M; Shiffman, ML; Silva, GF; Stanciu, C; Thommes, JA | 1 |
Abdo, AA; Ahmed, LR; Al-hamoudi, W; Al-Husseini, H; Al-Otaibi, MM; Albenmousa, A; Ali, SM; AlQaraawi, AM; AlSheikh, A; Alswat, KA; Hersi, A; Sanai, FM; Syed, M | 1 |
Albrecht, J; Berg, T; Boparai, N; Brass, C; Bruix, J; Burroughs, M; Carrilho, F; Colombo, M; Craxi, A; Diago, M; Flamm, S; Gonçales, F; Griffel, L; Heathcote, EJ; McGarrity, T; Moreno-Otero, R; Munteanu, M; Poynard, T; Schiff, E; Schmidt, W; Silva, M; Terg, R | 1 |
Borro, P; Testino, G | 1 |
Sanyal, AJ | 1 |
Jahan, S; Khaliq, S; Pervaiz, A | 1 |
Duarte-Rojo, A; Feld, JJ; Heathcote, EJ | 1 |
Abdurakhmanov, DT; Baĭzhanova, ZhZh; Ignatova, TM; Nekrasova, TP | 1 |
Cabibi, D; Cammà, C; Craxì, A; Di Marco, V; Di Stefano, R; Marchesini, G; Petta, S | 1 |
Amanzada, A; Blaschke, M; Goralczyk, A; Mihm, S; Moriconi, F; Ramadori, G; Schaefer, IM; van Thiel, D | 1 |
Bibert, S; Bochud, PY; Cerny, A; Dollenmaier, G; Dufour, JF; Gerlach, TJ; Heim, MH; Kutalik, Z; Lange, CM; Malinverni, R; Moradpour, D; Morikawa, K; Müllhaupt, B; Negro, F | 1 |
Ando, K; Fujinami, A; Fukuda, K; Hasegawa, Y; Hayashi, Y; Hotta, H; Imoto, S; Kim, KI; Kim, SR; Komaki, T; Kudo, M; Maekawa, Y; Nagata, Y; Nakajima, T; Ohta, M; Ohtani, A; Otono, Y; Saito, J; Sugimoto, K | 1 |
Abe, H; Arihiro, K; Chayama, K; Hayes, CN; Hiraga, N; Hyogo, H; Imamura, M; Kimura, Y; Kohno, T; Miki, D; Ochi, H; Ohnishi, M; Takahashi, S; Tanaka, S; Tsuge, M; Zhang, Y | 1 |
Balistreri, W; Barton, BA; Duggan, C; Gonzalez-Peralta, RP; Haber, B; Jonas, MM; Lobritto, S; Mitchell, PD; Mohan, P; Molleston, JP; Murray, KF; Narkewicz, MR; Rosenthal, P; Schwarz, KB; Shepherd, JA | 1 |
Adinolfi, LE; Guerrera, B; Restivo, L; Ruggiero, L; Zampino, R | 1 |
Bibert, S; Bochud, PY; Guedj, H; Guedj, J; Lagging, M; Negro, F; Neumann, AU; Westin, J | 1 |
Cabibi, D; Cammà, C; Craxì, A; Di Marco, V; Handberg, A; Macaluso, FS; Marchesini, G; Petta, S | 1 |
Albrecht, J; Goodman, Z; Manns, M; McHutchison, J; Poynard, T; Ratziu, V; Younossi, Z; Zeuzem, S | 1 |
Dimitropoulou, D; Gogos, CA; Labropoulou-Karatza, C; Siagris, D; Theocharis, GJ; Thomopoulos, KC; Tsamantas, AC | 1 |
Baldo, V; Bozzola, L; Carlotto, A; de Lalla, F; Fabris, P; Floreani, A; Giordani, MT; Negro, F; Rassu, M; Tramarin, A | 1 |
Bacon, BR; Brunt, EM; Di Bisceglie, AM; Harrison, SA; Neuschwander-Tetri, BA; Oliver, DA; Qazi, RA | 1 |
Fukunaga, K; Morita, M; Murao, S; Nishumi, T; Shibutani, Y; Tani, S; Uchikoga, O; Yagi, N | 1 |
Bianchi, FB; Granito, A; Guidi, M; Lenzi, M; Muratori, L; Muratori, P; Pappas, G | 1 |
Clouston, AD; Jonsson, JR; Lipka, GM; Powell, EE; Purdie, DM; Richardson, MM; Walsh, MJ | 1 |
Akuta, N; Arase, Y; Hosaka, T; Ikeda, K; Kobayashi, M; Kumada, H; Saitoh, S; Sato, J; Sezaki, H; Someya, T; Suzuki, F; Suzuki, Y; Watahiki, S | 1 |
Maier, KP | 1 |
Gui Qiang, W; Jian Wu, Y; Shu Chen, L | 1 |
Bejarano, PA; Casanova-Romero, PY; Martinez, EJ; Mindikoglu, AL; Regev, A; Schiff, ER; Tzakis, AG | 1 |
Chen, CH; Eng, HL; Hu, TH; Hung, CH; Kuo, FY; Lee, CM; Lu, SN; Wang, JH | 1 |
Antúnez, I; Aponte, N; Fernández-Carbia, A; Rodríguez-Perez, F; Toro, DH | 1 |
Ansaldi, F; Gentile, R; Icardi, G; Ravetti, G; Sumberaz, A; Testino, G | 1 |
Alessandri, A; Franco, V; Giannitrapani, L; Montalto, G; Rappa, F; Soresi, M; Tripi, S; Vuturo, O | 1 |
Afdhal, NH; Conjeevaram, HS; Everhart, JE; Hoofnagle, JH; Kleiner, DE; Wahed, AS; Zacks, S | 1 |
Dhillon, AP; Hellstrand, K; Lagging, M; Missale, G; Negro, F; Neumann, AU; Norkrans, G; Pawlotsky, JM; Romero, AI; Schalm, SW; Verheij-Hart, E; Westin, J; Zeuzem, S | 1 |
Bini, EJ; Bräu, N; Cheung, RC; Currie, SL; Ho, SB; Hu, KQ; Jeffers, L; McCracken, JD; Morgan, T; Schmidt, WN; Shen, H; Wright, TL | 1 |
Bonkovsky, HL; Chung, RT; Di Bisceglie, AM; Everhart, JE; Everson, GT; Ghany, MG; Greenson, JK; Lee, WM; Lindsay, KL; Lok, AS; Morgan, TR; Morishima, C; Padmanabhan, L; Shiffman, ML | 1 |
Almasio, PL; Amato, M; Craxí, A; De Lisi, S; Di Marco, V; Ferraro, D; Giordano, C; Lo Iacono, O; Mineo, C; Petta, S; Rodolico, V; Venezia, G | 1 |
Aida, K; Kurihara, H; Mikami, M; Nagashima, I; Shiga, J; Takikawa, H; Tanaka, A; Uegaki, S | 1 |
Cammalleri, L; Colonna, V; Cristaldi, E; Gargante, MP; Malaguarnera, M; Romano, M; Vacante, M | 1 |
Ackrill, A; Bernstein, D; Bodenheimer, H; Dienstag, JL; Govindarajan, S; Hadziyannis, SJ; Marcellin, P; Messinger, D; Rakela, J; Reddy, KR; Schmidt, G | 1 |
Dalekos, GN; Germenis, A; Liaskos, C; Makaritsis, K; Rigopoulou, EI; Togousidis, E; Zografos, TA | 1 |
Cacoub, P; Saadoun, D; Sène, D | 1 |
Abdel-Hamid, M; Attala, M; El Hoseiny, M; El Makhzangy, H; Esmat, G; Fontanet, A; Gad, RR; Hasan, A; Males, S; Mohamed, MK; Shouman, S; Zalata, K | 1 |
5 review(s) available for ribavirin and Fatty Liver
Article | Year |
---|---|
[Role of tenofovir in HIV and hepatitis C virus coinfection].
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antiviral Agents; Chemical and Drug Induced Liver Injury; Disease Progression; Drug Hypersensitivity; Drug Interactions; Drug Therapy, Combination; Fatty Liver; Glucose Metabolism Disorders; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Liver; Liver Cirrhosis; Organophosphonates; Reverse Transcriptase Inhibitors; Ribavirin; Tenofovir | 2008 |
Sequence variability of HCV Core region: important predictors of HCV induced pathogenesis and viral production.
Topics: Carcinoma, Hepatocellular; Cell Cycle; Drug Therapy, Combination; Fatty Liver; Genetic Variation; Hepacivirus; Hepatitis C Antigens; Hepatitis C, Chronic; Humans; Insulin Resistance; Interferons; Liver Neoplasms; Ribavirin; Viral Core Proteins; Virus Replication | 2011 |
'Easy to treat' genotypes were not created equal: can rapid virological response (RVR) level the playing field?
Topics: Antiviral Agents; Clinical Trials as Topic; Drug Resistance, Viral; Fatty Liver; Genotype; Hepacivirus; Hepatitis C, Chronic; Host-Pathogen Interactions; Humans; Insulin Resistance; Interferon Type I; Ribavirin; RNA, Viral; Treatment Outcome | 2011 |
[Drug therapy in chronic liver disease].
Topics: Adenine; Administration, Oral; Anti-HIV Agents; Antiviral Agents; Azathioprine; Cholangitis, Sclerosing; Chronic Disease; Drug Therapy, Combination; Fatty Liver; Hemochromatosis; Hepatitis B, Chronic; Hepatitis C, Chronic; Hepatitis, Autoimmune; Hepatolenticular Degeneration; Humans; Immunosuppression Therapy; Interferons; Lamivudine; Liver Cirrhosis, Biliary; Liver Diseases; Organophosphonates; Prednisolone; Prognosis; Prospective Studies; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Ribavirin; Time Factors | 2005 |
[Cryoglobulinemia].
Topics: Alcohol Drinking; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antiviral Agents; Cryoglobulinemia; Drug Therapy, Combination; Fatty Liver; Female; Hepatitis C; Humans; Immunologic Factors; Interferon-alpha; Liver Cirrhosis; Male; Recurrence; Ribavirin; Rituximab; Sex Factors; Vasculitis | 2008 |
14 trial(s) available for ribavirin and Fatty Liver
Article | Year |
---|---|
Hepatitis C Direct Acting Antivirals and Ribavirin Modify Lipid but not Glucose Parameters.
Topics: Antiviral Agents; Apolipoproteins; Fatty Liver; Female; Glucose; Hepacivirus; Hepatitis C, Chronic; Homeostasis; Humans; Insulin Resistance; Lipids; Liver; Male; Middle Aged; Ribavirin; Treatment Outcome | 2019 |
Evolution of hepatic steatosis in patients with advanced hepatitis C: results from the hepatitis C antiviral long-term treatment against cirrhosis (HALT-C) trial.
Topics: Antiviral Agents; Disease Progression; Fatty Liver; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Time Factors | 2009 |
Effect of liver steatosis on therapeutic response in chronic hepatitis C virus genotype 1 infected patients in hungary.
Topics: Antiviral Agents; Fatty Liver; Hepacivirus; Hepatitis C, Chronic; Humans; Hungary; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2010 |
Pegylated interferon alfa-2a and ribavirin treatment for recurrent hepatitis C: role of steatosis and body mass index.
Topics: Adult; Antiviral Agents; Biopsy; Body Mass Index; Drug Therapy, Combination; Fatty Liver; Female; Hepatitis C, Chronic; Humans; Immunosuppressive Agents; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Recurrence; Ribavirin; Severity of Illness Index; Time Factors; Treatment Outcome; Viral Load | 2009 |
Induction pegylated interferon alfa-2a and high dose ribavirin do not increase SVR in heavy patients with HCV genotype 1 and high viral loads.
Topics: Adult; Antiviral Agents; Body Weight; Dose-Response Relationship, Drug; Drug Therapy, Combination; Fatty Liver; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Obesity; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Viral Load | 2010 |
FibroTest is an independent predictor of virologic response in chronic hepatitis C patients retreated with pegylated interferon alfa-2b and ribavirin in the EPIC³ program.
Topics: Adult; Alanine Transaminase; Biopsy; Drug Therapy, Combination; Fatty Liver; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Prognosis; Prospective Studies; Recombinant Proteins; Ribavirin | 2011 |
Pegylated interferon for chronic hepatitis C in children affects growth and body composition: results from the pediatric study of hepatitis C (PEDS-C) trial.
Topics: Adolescent; Antiviral Agents; Body Composition; Body Height; Body Mass Index; Body Weight; Child; Child, Preschool; Cohort Studies; Drug Therapy, Combination; Eating; Fatty Liver; Female; Growth Disorders; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2012 |
Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C.
Topics: Adult; Antiviral Agents; Cholesterol; Drug Therapy, Combination; Fatty Liver; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Prevalence; Recombinant Proteins; Ribavirin | 2003 |
Effects of fatty liver and related factors on the efficacy of combination antiviral therapy in patients with chronic hepatitis C.
Topics: Adult; Antiviral Agents; China; Drug Therapy, Combination; Fatty Liver; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Injections, Subcutaneous; Insulin; Insulin Resistance; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Ultrasonography | 2006 |
Impact of steatosis on long-term histological outcome in chronic hepatitis C after antiviral therapy.
Topics: Adult; Aged; Antiviral Agents; Biopsy; Disease Progression; Fatty Liver; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Male; Middle Aged; Recombinant Proteins; Ribavirin; RNA, Viral | 2006 |
Impact of hepatic steatosis on viral kinetics and treatment outcome during antiviral treatment of chronic HCV infection.
Topics: Adult; Antiviral Agents; Biopsy; Fatty Liver; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Kaplan-Meier Estimate; Kinetics; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome | 2007 |
Clinical implications of hepatic steatosis in patients with chronic hepatitis C: a multicenter study of U.S. veterans.
Topics: Adult; Aged; Antiviral Agents; Body Mass Index; Fatty Liver; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Hospitals, Veterans; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Obesity; Prevalence; Prospective Studies; Recombinant Proteins; Ribavirin; Risk Factors; Severity of Illness Index; Treatment Outcome; United States | 2007 |
Hepatic steatosis in hepatitis C: comparison of diabetic and nondiabetic patients in the hepatitis C antiviral long-term treatment against cirrhosis trial.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Diabetes Mellitus; Disease Progression; Fatty Liver; Female; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Prevalence; Prospective Studies; Recombinant Proteins; Ribavirin; Risk Factors | 2007 |
L-carnitine treatment reduces steatosis in patients with chronic hepatitis C treated with alpha-interferon and ribavirin.
Topics: Adult; Antiviral Agents; Carnitine; Drug Therapy, Combination; Fatty Liver; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Function Tests; Male; Middle Aged; Ribavirin; Vitamin B Complex | 2008 |
49 other study(ies) available for ribavirin and Fatty Liver
Article | Year |
---|---|
Association between PNPLA3[G]/I148M variant, steatosis and fibrosis stage in hepatitis C virus - genetic matters.
Topics: Antiviral Agents; Disease Progression; Fatty Liver; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lipase; Liver; Liver Cirrhosis; Male; Membrane Proteins; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; RNA, Viral | 2019 |
Interferon-γ-inducible protein-10 in chronic hepatitis C: Correlations with insulin resistance, histological features & sustained virological response.
Topics: Adult; Aged; Antiviral Agents; Biopsy; Chemokine CXCL10; Enzyme-Linked Immunosorbent Assay; Fatty Liver; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Insulin Resistance; Interferon-gamma; Liver; Male; Middle Aged; Ribavirin; Treatment Outcome; Viral Load | 2017 |
Direct-acting antiviral agents against hepatitis C virus and lipid metabolism.
Topics: Antiviral Agents; Cholesterol; Drug Therapy, Combination; Fatty Liver; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Lipid Metabolism; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Triglycerides | 2017 |
Association of
Topics: Adult; Aged; Antiviral Agents; Fatty Liver; Female; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Retrospective Studies; Ribavirin | 2017 |
The association between steatosis and diabetes with hepatocellular carcinoma in non-genotype 3 chronic hepatitis C patients.
Topics: Adult; Antiviral Agents; Carcinoma, Hepatocellular; Diabetes Complications; Diabetes Mellitus; Fatty Liver; Female; Genotype; Hepatitis C, Chronic; Humans; Interferons; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Proportional Hazards Models; Retrospective Studies; Ribavirin; Risk Factors; Sustained Virologic Response; Taiwan | 2018 |
Predictors of treatment efficacy and liver stiffness changes following therapy with Sofosbuvir plus Ribavirin in patients infected with HCV genotype 2.
Topics: Adult; Aged; Aged, 80 and over; alpha-Fetoproteins; Antiviral Agents; Drug Therapy, Combination; Fatty Liver; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver; Liver Cirrhosis; Male; Middle Aged; Prognosis; Retrospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Young Adult | 2018 |
Liver steatosis and dyslipidemia after HCV eradication by direct acting antiviral agents are synergistic risks of atherosclerosis.
Topics: Adult; Aged; Antiviral Agents; Atherosclerosis; Cholesterol, LDL; Dyslipidemias; Fatty Liver; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Lipid Metabolism; Liver; Male; Middle Aged; Ribavirin; Risk Factors; Sustained Virologic Response | 2018 |
Risk factors for remaining liver injury in patients with virological elimination of chronic hepatitis C.
Topics: Alanine Transaminase; Antiviral Agents; Fatty Liver; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Obesity; Prospective Studies; Ribavirin; Risk Factors; Sex Factors | 2019 |
Association between hepatic steatosis and hepatic expression of genes involved in innate immunity in patients with chronic hepatitis C.
Topics: Adaptor Proteins, Signal Transducing; Antiviral Agents; DEAD Box Protein 58; DEAD-box RNA Helicases; Drug Resistance, Viral; Drug Therapy, Combination; Fatty Liver; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Immunity, Innate; Interferon alpha-2; Interferon-alpha; Liver; Male; Middle Aged; Polyethylene Glycols; Receptors, Immunologic; Recombinant Proteins; Ribavirin; RNA, Messenger; Ubiquitin-Protein Ligases | 2013 |
Role of FDFT1 polymorphism for fibrosis progression in patients with chronic hepatitis C.
Topics: Adult; Alleles; Antiviral Agents; Disease Progression; Farnesyl-Diphosphate Farnesyltransferase; Fatty Liver; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Logistic Models; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; Risk Factors; RNA, Viral | 2014 |
Ultrasound based evaluation of hepatic steatosis and fibrosis in hepatitis C non-responders.
Topics: Adult; Aged; Biopsy; Cross-Sectional Studies; Fatty Liver; Female; Fibrosis; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Male; Middle Aged; Predictive Value of Tests; Ribavirin; Sensitivity and Specificity; Treatment Failure; Ultrasonography; Young Adult | 2013 |
Lymphocytes degranulation in liver in hepatitis C virus carriers is associated with IFNL4 polymorphisms and ALT levels.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Cell Degranulation; Fatty Liver; Female; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Interleukins; Liver; Lymphocytes; Lysosomal-Associated Membrane Protein 1; Male; Middle Aged; Multivariate Analysis; Natural Killer T-Cells; Non-alcoholic Fatty Liver Disease; Polymorphism, Genetic; Ribavirin; RNA, Viral; Viral Load | 2014 |
[Lipid kinetics during dual antiviral therapy in patients with chronic hepatitis C].
Topics: Adult; Antiviral Agents; Chemokine CXCL10; Cholesterol; Drug Therapy, Combination; False Positive Reactions; Fatty Liver; Female; Follow-Up Studies; Genotype; Hepatitis C, Chronic; Humans; Hypertriglyceridemia; Interferon-alpha; Interferons; Interleukins; Lipids; Lipoproteins; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Prospective Studies; Recombinant Proteins; Ribavirin; ROC Curve; Sensitivity and Specificity; Severity of Illness Index; Treatment Outcome; Viral Load; Viremia | 2015 |
Advanced hepatic fibrosis and steatosis are associated with persistent alanine aminotransferase elevation in chronic hepatitis C patients negative for hepatitis C virus RNA during pegylated interferon plus ribavirin therapy.
Topics: Adult; Aged; Alanine Transaminase; Antiviral Agents; Drug Therapy, Combination; Fatty Liver; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral | 2015 |
Ongoing liver inflammation in patients with chronic hepatitis C and sustained virological response.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Fatty Liver; Hepacivirus; Hepatitis; Hepatitis C, Chronic; Humans; Interferon-alpha; Logistic Models; Middle Aged; Multivariate Analysis; Outcome Assessment, Health Care; Polyethylene Glycols; Prospective Studies; Retrospective Studies; Ribavirin; Risk Factors; Sustained Virologic Response; Time Factors; Transaminases | 2017 |
Hepatic steatosis in patients with chronic hepatitis C virus genotype 2 or 3 does not affect viral response in patients treated with peginterferon alpha-2a (40KD) (PEGASYS) plus ribavirin (COPEGUS) for 16 or 24 weeks.
Topics: Age Factors; Body Weight; Fatty Liver; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Logistic Models; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Viral Load | 2009 |
[Influence of weight reduction on the effectiveness of combined peginterferon and ribavirin treatment in chronic HCV hepatitis].
Topics: Amantadine; Antioxidants; Antiviral Agents; Drug Therapy, Combination; Fatty Liver; Hepatitis C, Chronic; Humans; Insulin Resistance; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Obesity; Polyethylene Glycols; Protective Agents; Recombinant Proteins; Ribavirin; Silymarin; Treatment Outcome; Weight Loss | 2008 |
Patients achieving clearance of HCV with interferon therapy recover from decreased retinol-binding protein 4 levels.
Topics: Aged; Antiviral Agents; Fatty Liver; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Liver Cirrhosis; Male; Middle Aged; Plasma; Polyethylene Glycols; Recombinant Proteins; Retinol-Binding Proteins, Plasma; Ribavirin; Severity of Illness Index; Viral Load | 2009 |
Sustained virological response during exenatide treatment in a patient with hepatitis C and nonalcoholic steatohepatitis.
Topics: Antiviral Agents; Drug Therapy, Combination; Exenatide; Fatty Liver; Hepatitis C, Chronic; Humans; Hypoglycemic Agents; Interferon alpha-2; Interferon-alpha; Liver Function Tests; Male; Middle Aged; Peptides; Recombinant Proteins; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin; Venoms; Viral Load | 2009 |
Do steatosis and steatohepatitis impact on sustained virological response (SVR) rates in patients receiving pegylated interferon and ribavirin for chronic hepatitis C infection?
Topics: Adult; Antiviral Agents; Biopsy; Fatty Liver; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Histocytochemistry; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2010 |
Prevalence and impact of hepatic steatosis on the response to antiviral therapy in Saudi patients with genotypes 1 and 4 chronic hepatitis C.
Topics: Adult; Antiviral Agents; Biopsy; Body Mass Index; Diabetes Mellitus; Fatty Liver; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Hyperlipidemias; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prevalence; Recombinant Proteins; Retrospective Studies; Ribavirin; Saudi Arabia; Severity of Illness Index | 2011 |
Hepatitis C recurrence: influence of serum cholesterol levels and liver steatosis on antiviral therapy.
Topics: Antiviral Agents; Body Mass Index; Cholesterol; Fatty Liver; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; Triglycerides; Viral Load | 2011 |
Role of insulin resistance and hepatic steatosis in the progression of fibrosis and response to treatment in hepatitis C.
Topics: Antiviral Agents; Fatty Liver; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Insulin Resistance; Interferon alpha-2; Interferon-alpha; MicroRNAs; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2011 |
[Metabolic syndrome in patients with chronic hepatitis C genotype 1].
Topics: Adult; Antiviral Agents; Fatty Liver; Female; Genome, Viral; Hepacivirus; Hepatitis C, Chronic; Hepatocytes; Humans; Insulin Resistance; Interferon alpha-2; Interferon-alpha; Leptin; Liver Cirrhosis; Male; Metabolic Syndrome; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Severity of Illness Index; Treatment Outcome | 2011 |
TyG index, HOMA score and viral load in patients with chronic hepatitis C due to genotype 1.
Topics: Adult; Aged; Antiviral Agents; Blood Glucose; Body Mass Index; Drug Therapy, Combination; Fatty Liver; Female; Hepacivirus; Hepatitis C, Chronic; Homeostasis; Humans; Insulin Resistance; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Triglycerides; Viral Load | 2011 |
Ultra-rapid virological response, young age, low γ-GT/ALT-ratio, and absence of steatosis identify a subgroup of HCV Genotype 3 patients who achieve SVR with IFN-α(2a) monotherapy.
Topics: Adult; Age Factors; Alanine Transaminase; Antiviral Agents; Drug Therapy, Combination; Fatty Liver; Female; gamma-Glutamyltransferase; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Male; Middle Aged; Polymorphism, Single Nucleotide; Recombinant Proteins; Retrospective Studies; Ribavirin; Young Adult | 2011 |
Serum ferritin levels are associated with a distinct phenotype of chronic hepatitis C poorly responding to pegylated interferon-alpha and ribavirin therapy.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Biomarkers; Drug Therapy, Combination; Fatty Liver; Female; Ferritins; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Incidence; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Phenotype; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Risk Factors; Treatment Outcome; Young Adult | 2012 |
Correlation between insulin resistance and outcome of pegylated interferon and ribavirin therapy, hepatic steatosis, hepatic fibrosis in chronic hepatitis C-1b and high viral load.
Topics: Aged; Antiviral Agents; Body Mass Index; Drug Therapy, Combination; Fatty Liver; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Insulin Resistance; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load | 2011 |
IL28B polymorphism is associated with fatty change in the liver of chronic hepatitis C patients.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Fatty Liver; Female; Genotype; Hepatitis C, Chronic; Humans; Interferons; Interleukins; Liver; Logistic Models; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Ribavirin; Young Adult | 2012 |
Steatosis is the predictor of relapse in HCV genotype 3- but not 2-infected patients treated with 12 weeks of pegylated interferon-α-2a plus ribavirin and RVR.
Topics: Adult; Antiviral Agents; Fatty Liver; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prognosis; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Treatment Outcome | 2012 |
The impact of fibrosis and steatosis on early viral kinetics in HCV genotype 1-infected patients treated with Peg-IFN-alfa-2a and ribavirin.
Topics: Adult; Antiviral Agents; Fatty Liver; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load | 2012 |
High sCD36 plasma level is associated with steatosis and its severity in patients with genotype 1 chronic hepatitis C.
Topics: Adult; Aged; Antiviral Agents; Biomarkers; Biopsy; CD36 Antigens; Enzyme-Linked Immunosorbent Assay; Fatty Liver; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Liver; Male; Middle Aged; Plasma; Ribavirin; Severity of Illness Index | 2013 |
Liver steatosis is an independent risk factor for treatment failure in patients with chronic hepatitis C.
Topics: Adolescent; Adult; Age Factors; Aged; Antiviral Agents; Body Mass Index; Drug Therapy, Combination; Fatty Liver; Female; Genotype; Hepatitis C, Chronic; Humans; Interferons; Logistic Models; Male; Middle Aged; Retrospective Studies; Ribavirin; Risk Factors; Treatment Failure | 2005 |
Impact of liver steatosis on virological response in [corrected] Italian patients with chronic hepatitis C treated with peg-interferon alpha-2b plus ribavarin.
Topics: Adult; Antiviral Agents; Drug Evaluation; Drug Therapy, Combination; Fatty Liver; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Treatment Outcome | 2005 |
Effect of significant histologic steatosis or steatohepatitis on response to antiviral therapy in patients with chronic hepatitis C.
Topics: Antiviral Agents; Biopsy; Fatty Liver; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Odds Ratio; Retrospective Studies; Ribavirin; RNA, Viral; Severity of Illness Index; Treatment Outcome; Virulence | 2005 |
[Type 2 diabetes mellitus with histological finding of nonalcoholic steatohepatitis following combination therapy with interferon and ribavirin for chronic hepatitis C].
Topics: Adult; Antiviral Agents; Chemical and Drug Induced Liver Injury; Diabetes Mellitus, Type 2; Fatty Liver; Hepatitis C, Chronic; Humans; Interferons; Male; Ribavirin | 2005 |
Hepatic steatosis in chronic hepatitis C: impact on response to anti-viral treatment with peg-interferon and ribavirin.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Fatty Liver; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2005 |
Non-response to antiviral therapy is associated with obesity and increased hepatic expression of suppressor of cytokine signalling 3 (SOCS-3) in patients with chronic hepatitis C, viral genotype 1.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Fatty Liver; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Immunohistochemistry; Insulin Resistance; Interferon alpha-2; Interferon-alpha; Liver; Male; Middle Aged; Obesity; Phosphoenolpyruvate Carboxykinase (GTP); Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Signal Transduction; Suppressor of Cytokine Signaling 3 Protein; Suppressor of Cytokine Signaling Proteins; Treatment Outcome | 2006 |
Predictive factors of virological non-response to interferon-ribavirin combination therapy for patients infected with hepatitis C virus of genotype 1b and high viral load.
Topics: Adult; Aged; Amino Acid Substitution; Antiviral Agents; Case-Control Studies; Drug Therapy, Combination; Fatty Liver; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferons; Male; Middle Aged; Mutation, Missense; Ribavirin; Risk Factors; RNA, Viral; Treatment Outcome; Viral Load | 2006 |
The impact of nonalcoholic fatty liver disease and the metabolic syndrome on progression of fibrosis in patients with recurrent HCV after liver transplantation.
Topics: Adult; Antiviral Agents; Biopsy; Cholesterol, HDL; Disease Progression; Fatty Liver; Female; Hepatitis C; Humans; Liver Cirrhosis; Living Donors; Male; Metabolic Syndrome; Middle Aged; Postoperative Complications; Recurrence; Retrospective Studies; Ribavirin; Triglycerides | 2006 |
Steatosis as a predictive factor for treatment response in patients with chronic hepatitis C.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Fatty Liver; Female; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Prognosis; Retrospective Studies; Ribavirin; Risk Factors; Treatment Outcome | 2004 |
Pegylated interferon (PEG-IFN) alfa-2b and ribavirin for recurrent hepatitis C (genotype 1) after liver transplantation: relationship with steatosis.
Topics: Adult; Antiviral Agents; Body Mass Index; Cholesterol; Drug Therapy, Combination; Fatty Liver; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Prospective Studies; Recombinant Proteins; Recurrence; Ribavirin; Triglycerides | 2006 |
Impact of liver steatosis on the antiviral response in the hepatitis C virus-associated chronic hepatitis.
Topics: Adult; Aging; Alanine Transaminase; Antiviral Agents; Aspartate Aminotransferases; Body Mass Index; Drug Therapy, Combination; Fatty Liver; Female; gamma-Glutamyltransferase; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Severity of Illness Index; Treatment Outcome | 2006 |
Race, insulin resistance and hepatic steatosis in chronic hepatitis C.
Topics: Adult; Antiviral Agents; Black or African American; Drug Therapy, Combination; Fatty Liver; Female; Hepatitis C, Chronic; Humans; Insulin Resistance; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Multivariate Analysis; Polyethylene Glycols; Prevalence; Prospective Studies; Recombinant Proteins; Ribavirin; Severity of Illness Index; Signal Transduction; White People | 2007 |
The impact of insulin resistance, serum adipocytokines and visceral obesity on steatosis and fibrosis in patients with chronic hepatitis C.
Topics: Adipocytes; Adult; Antiviral Agents; Fatty Liver; Female; Hepatitis C, Chronic; Humans; Insulin Resistance; Interferon alpha-2; Interferon-alpha; Intra-Abdominal Fat; Liver Cirrhosis; Male; Middle Aged; Obesity; Recombinant Proteins; Ribavirin | 2007 |
Hepatic steatosis as a possible risk factor for the development of hepatocellular carcinoma after eradication of hepatitis C virus with antiviral therapy in patients with chronic hepatitis C.
Topics: Aged; Antiviral Agents; Carcinoma, Hepatocellular; Fatty Liver; Female; Follow-Up Studies; Hepacivirus; Hepatitis C; Humans; Interferons; Kaplan-Meier Estimate; Liver; Liver Neoplasms; Male; Middle Aged; Retrospective Studies; Ribavirin; Risk Factors; RNA, Viral | 2007 |
Hepatic steatosis in chronic hepatitis C: baseline host and viral characteristics and influence on response to therapy with peginterferon alpha-2a plus ribavirin.
Topics: Antiviral Agents; Clinical Trials as Topic; Drug Combinations; Fatty Liver; Genotype; Hepacivirus; Hepatitis C, Chronic; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Retrospective Studies; Ribavirin | 2008 |
Adiponectin: a new independent predictor of liver steatosis and response to IFN-alpha treatment in chronic hepatitis C.
Topics: Adiponectin; Adult; Antiviral Agents; Biomarkers; Body Mass Index; Drug Therapy, Combination; Fatty Liver; Female; Genotype; Hepacivirus; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Ribavirin; RNA, Viral; Tumor Necrosis Factor-alpha | 2008 |
Predictors of a sustained virological response in patients with genotype 4 chronic hepatitis C.
Topics: Adult; alpha-Fetoproteins; Antiviral Agents; Fatty Liver; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Logistic Models; Male; Medication Adherence; Middle Aged; Multivariate Analysis; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome | 2008 |